Singapore markets closed
  • Straits Times Index

    3,157.97
    -4.53 (-0.14%)
     
  • Nikkei

    28,948.73
    -9.83 (-0.03%)
     
  • Hang Seng

    28,842.13
    +103.25 (+0.36%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • BTC-USD

    35,540.20
    -1,819.55 (-4.87%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • Dow

    34,479.60
    +13.36 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.09 (+0.35%)
     
  • Gold

    1,879.50
    -16.90 (-0.89%)
     
  • Crude Oil

    70.78
    +0.49 (+0.70%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • FTSE Bursa Malaysia

    1,575.16
    -4.74 (-0.30%)
     
  • Jakarta Composite Index

    6,095.50
    -12.04 (-0.20%)
     
  • PSE Index

    6,907.79
    +32.08 (+0.47%)
     

Insights on the Thyroid Cancer Diagnostics Global Market to 2028 - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

·3-min read

The "Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Type; By Technique; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global thyroid cancer diagnostics market size is expected to reach USD 3.84 billion by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

The high prevalence rate of thyroid cancer in the market, huge unmet medical needs, drug approvals, and research initiatives to deal with early diagnosis are the prominent drivers responsible for the market growth. It is being estimated that each year, around 53,000 people in the U.S. alone expected to diagnose with thyroid cancer. Approximately, 30 percent of all cancer cases are metastasized, found near to the lymph nodes. This is likely to drive the demand for diagnostics in the country.

Moreover, it is being found that NTRK genes, which are responsible for tumor growth in few cancers are most common in people induced with RAIR thyroid. In December 2020, the U.S.-based precision medicine company, Blueprint Medicines Corporation, announced the approval of pralsetinib for people induced with RET altered thyroid cancers by the USFDA. RET-activated mutations are key instigators in many cancer forms, including thyroid cancers. RET fusions are implicated in around 10 to 20% of the patients suffering from papillary thyroid cancers.

Companies Mentioned

  • Abbott

  • Roche Ltd

  • Thermo Fisher Scientific

  • Siemens Healthcare

  • Bio-Rad Laboratories

  • General Electric

  • Koninklijke Philips

  • Toshiba Corporation

  • Agilent Technologies

  • Illumina Inc.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Thyroid Cancer Diagnostics Market Insights

4.1. Thyroid Cancer Diagnostics - Industry Snapshot

4.2. Thyroid Cancer Diagnostics Market Dynamics

4.3. Porter's Five Forces Analysis

4.4. PESTLE Analysis

4.5. Thyroid Cancer Diagnostics Market Industry trends

5. Thyroid Cancer Diagnostics Market Assessment by Type

5.1. Key Findings

5.2. Introduction

5.3. Papillary Carcinoma

5.4. Follicular Carcinoma

5.5. Others

6. Global Thyroid Cancer Diagnostics Market, by Technique

6.1. Key Findings

6.2. Introduction

6.3. Blood Tests

6.4. Imaging

6.5. Biopsy

6.6. Others

7. Thyroid Cancer Diagnostics Market Assessment by End-Use

7.1. Key Findings

7.2. Introduction

7.3. Hospital Laboratories

7.4. Cancer Diagnostic Centers

7.5. Research Institutes

7.6. Others

8. Thyroid Cancer Diagnostics Market Assessment by Geography

8.1. Key findings

8.2. Introduction

8.3. Thyroid Cancer Diagnostics Market - North America

8.4. Thyroid Cancer Diagnostics Market - Europe

8.5. Thyroid Cancer Diagnostics Market - Asia-Pacific

8.6. Thyroid Cancer Diagnostics Market - Middle East & Africa

8.7. Thyroid Cancer Diagnostics Market - Latin America

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis

9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/4z03i

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005549/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900